Veracyte Common Stock vs Accounts Payable Analysis

VCYT Stock

USD 20.63 0.51 2.53%

Veracyte financial indicator trend analysis is much more than just breaking down Veracyte prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Veracyte is a good investment. Please check the relationship between Veracyte Common Stock and its Accounts Payable accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veracyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.

Common Stock vs Accounts Payable

Common Stock vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Veracyte Common Stock account and Accounts Payable. At this time, the significance of the direction appears to have strong relationship.

The correlation between Veracyte's Common Stock and Accounts Payable is 0.7. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Veracyte, assuming nothing else is changed. The correlation between historical values of Veracyte's Common Stock and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Veracyte are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Common Stock i.e., Veracyte's Common Stock and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.7

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Common Stock

Accounts Payable

An accounting item on the balance sheet that represents Veracyte obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Veracyte are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Veracyte's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Veracyte current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veracyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.At this time, Veracyte's Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 392.7 K in 2024, whereas Issuance Of Capital Stock is likely to drop 0.00 in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	227.0M	236.0M	235.2M	247.0M
Cost Of Revenue	74.4M	101.6M	137.9M	144.8M

Total Operating Expenses Cost Of Revenue

Veracyte fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Property Plant Equipment
Total Assets		0.98	0.98	1.0	0.76	0.96	-0.68	-0.88	0.9	0.61	0.98	-0.5	0.3	0.63	0.98	0.9	0.84	0.49	0.95	0.84	0.99	0.94	0.88	0.72	0.8	0.96
Other Current Liab	0.98		1.0	0.98	0.74	0.95	-0.58	-0.85	0.95	0.51	0.99	-0.51	0.2	0.54	0.96	0.89	0.81	0.51	0.96	0.84	0.97	0.96	0.88	0.65	0.79	0.97
Total Current Liabilities	0.98	1.0		0.98	0.73	0.94	-0.57	-0.85	0.96	0.5	0.99	-0.51	0.18	0.53	0.96	0.88	0.8	0.49	0.96	0.84	0.97	0.95	0.88	0.64	0.78	0.97
Total Stockholder Equity	1.0	0.98	0.98		0.75	0.96	-0.68	-0.87	0.9	0.61	0.98	-0.5	0.3	0.63	0.97	0.89	0.84	0.48	0.94	0.84	0.99	0.93	0.88	0.73	0.8	0.96
Other Liab	0.76	0.74	0.73	0.75		0.81	-0.7	-0.73	0.61	0.74	0.7	-0.56	0.5	0.74	0.76	0.77	0.84	0.65	0.66	0.83	0.76	0.76	0.56	0.81	0.84	0.71
Property Plant And Equipment Net	0.96	0.95	0.94	0.96	0.81		-0.71	-0.94	0.85	0.66	0.93	-0.44	0.34	0.68	0.98	0.96	0.9	0.63	0.96	0.81	0.98	0.96	0.88	0.77	0.88	0.96
Net Debt	-0.68	-0.58	-0.57	-0.68	-0.7	-0.71		0.69	-0.48	-0.97	-0.54	0.11	-0.7	-0.97	-0.68	-0.77	-0.71	-0.41	-0.61	-0.46	-0.69	-0.59	-0.57	-0.94	-0.74	-0.56
Retained Earnings	-0.88	-0.85	-0.85	-0.87	-0.73	-0.94	0.69		-0.75	-0.65	-0.83	0.27	-0.34	-0.67	-0.94	-0.95	-0.92	-0.72	-0.91	-0.68	-0.94	-0.92	-0.86	-0.75	-0.87	-0.91
Accounts Payable	0.9	0.95	0.96	0.9	0.61	0.85	-0.48	-0.75		0.4	0.92	-0.43	0.07	0.42	0.87	0.82	0.68	0.42	0.92	0.76	0.89	0.9	0.85	0.52	0.7	0.91
Cash	0.61	0.51	0.5	0.61	0.74	0.66	-0.97	-0.65	0.4		0.46	-0.18	0.77	1.0	0.62	0.73	0.75	0.49	0.53	0.49	0.63	0.54	0.45	0.98	0.79	0.49
Non Current Assets Total	0.98	0.99	0.99	0.98	0.7	0.93	-0.54	-0.83	0.92	0.46		-0.54	0.17	0.49	0.95	0.84	0.79	0.45	0.93	0.86	0.96	0.93	0.87	0.6	0.73	0.96
Non Currrent Assets Other	-0.5	-0.51	-0.51	-0.5	-0.56	-0.44	0.11	0.27	-0.43	-0.18	-0.54		-0.37	-0.21	-0.42	-0.29	-0.49	-0.15	-0.3	-0.84	-0.44	-0.4	-0.08	-0.31	-0.45	-0.39
Other Assets	0.3	0.2	0.18	0.3	0.5	0.34	-0.7	-0.34	0.07	0.77	0.17	-0.37		0.79	0.29	0.38	0.53	0.21	0.16	0.35	0.32	0.19	-0.03	0.75	0.54	0.14
Cash And Short Term Investments	0.63	0.54	0.53	0.63	0.74	0.68	-0.97	-0.67	0.42	1.0	0.49	-0.21	0.79		0.64	0.74	0.77	0.48	0.55	0.51	0.65	0.56	0.46	0.99	0.81	0.51
Net Receivables	0.98	0.96	0.96	0.97	0.76	0.98	-0.68	-0.94	0.87	0.62	0.95	-0.42	0.29	0.64		0.95	0.89	0.62	0.97	0.8	0.99	0.97	0.9	0.74	0.85	0.97
Common Stock Total Equity	0.9	0.89	0.88	0.89	0.77	0.96	-0.77	-0.95	0.82	0.73	0.84	-0.29	0.38	0.74	0.95		0.88	0.72	0.93	0.7	0.94	0.95	0.86	0.81	0.92	0.91
Common Stock Shares Outstanding	0.84	0.81	0.8	0.84	0.84	0.9	-0.71	-0.92	0.68	0.75	0.79	-0.49	0.53	0.77	0.89	0.88		0.7	0.81	0.81	0.89	0.83	0.69	0.86	0.95	0.81
Non Current Liabilities Total	0.49	0.51	0.49	0.48	0.65	0.63	-0.41	-0.72	0.42	0.49	0.45	-0.15	0.21	0.48	0.62	0.72	0.7		0.57	0.49	0.57	0.71	0.53	0.55	0.77	0.6
Inventory	0.95	0.96	0.96	0.94	0.66	0.96	-0.61	-0.91	0.92	0.53	0.93	-0.3	0.16	0.55	0.97	0.93	0.81	0.57		0.7	0.96	0.96	0.95	0.65	0.8	0.97
Other Current Assets	0.84	0.84	0.84	0.84	0.83	0.81	-0.46	-0.68	0.76	0.49	0.86	-0.84	0.35	0.51	0.8	0.7	0.81	0.49	0.7		0.81	0.79	0.56	0.63	0.78	0.78
Other Stockholder Equity	0.99	0.97	0.97	0.99	0.76	0.98	-0.69	-0.94	0.89	0.63	0.96	-0.44	0.32	0.65	0.99	0.94	0.89	0.57	0.96	0.81		0.96	0.9	0.75	0.84	0.97
Total Liab	0.94	0.96	0.95	0.93	0.76	0.96	-0.59	-0.92	0.9	0.54	0.93	-0.4	0.19	0.56	0.97	0.95	0.83	0.71	0.96	0.79	0.96		0.9	0.66	0.84	0.98
Property Plant And Equipment Gross	0.88	0.88	0.88	0.88	0.56	0.88	-0.57	-0.86	0.85	0.45	0.87	-0.08	-0.03	0.46	0.9	0.86	0.69	0.53	0.95	0.56	0.9	0.9		0.54	0.65	0.94
Total Current Assets	0.72	0.65	0.64	0.73	0.81	0.77	-0.94	-0.75	0.52	0.98	0.6	-0.31	0.75	0.99	0.74	0.81	0.86	0.55	0.65	0.63	0.75	0.66	0.54		0.88	0.62
Common Stock	0.8	0.79	0.78	0.8	0.84	0.88	-0.74	-0.87	0.7	0.79	0.73	-0.45	0.54	0.81	0.85	0.92	0.95	0.77	0.8	0.78	0.84	0.84	0.65	0.88		0.78
Property Plant Equipment	0.96	0.97	0.97	0.96	0.71	0.96	-0.56	-0.91	0.91	0.49	0.96	-0.39	0.14	0.51	0.97	0.91	0.81	0.6	0.97	0.78	0.97	0.98	0.94	0.62	0.78

Click cells to compare fundamentals

Veracyte Account Relationship Matchups

Veracyte fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	275.2M	457.2M	1.2B	1.2B	1.1B	1.2B
Other Current Liab	13.7M	11.7M	42.4M	44.0M	41.2M	43.2M
Total Current Liabilities	17.5M	16.8M	64.2M	62.6M	61.2M	64.3M
Total Stockholder Equity	239.5M	421.2M	1.1B	1.1B	1.0B	1.1B
Other Liab	6.1M	8.4M	13.1M	7.6M	8.7M	5.6M
Property Plant And Equipment Net	17.7M	16.8M	31.1M	30.9M	30.9M	32.4M
Net Debt	(145.7M)	(337.0M)	(154.3M)	(139.5M)	(203.8M)	(193.6M)
Retained Earnings	(246.7M)	(281.6M)	(357.2M)	(393.7M)	(468.1M)	(444.7M)
Accounts Payable	2.3M	3.1M	12.4M	11.9M	12.9M	13.6M
Cash	159.3M	349.4M	173.2M	154.2M	216.5M	117.7M
Non Current Assets Total	87.5M	81.5M	944.7M	907.8M	852.2M	894.8M
Non Currrent Assets Other	2.0M	2.0M	(35.1M)	(26.8M)	6.0M	6.3M
Other Assets	2.0M	9.8M	2.9M	6.2M	1.0	0.95
Cash And Short Term Investments	159.3M	349.4M	173.2M	178.9M	216.5M	119.7M
Net Receivables	19.3M	18.5M	41.5M	44.0M	45.1M	47.3M
Common Stock Total Equity	50K	58K	71K	72K	82.8K	86.9K
Common Stock Shares Outstanding	46.1M	53.2M	67.9M	71.5M	72.6M	41.6M
Liabilities And Stockholders Equity	275.2M	457.2M	1.2B	1.2B	1.1B	1.2B
Non Current Liabilities Total	18.3M	19.2M	27.2M	18.6M	32.5M	19.6M
Inventory	6.8M	4.7M	11.2M	14.3M	16.1M	16.9M
Other Current Assets	2.2M	3.2M	17.2M	11.5M	8.0M	4.6M
Other Stockholder Equity	486.1M	702.8M	1.5B	1.5B	1.5B	1.6B
Total Liab	35.8M	35.9M	91.3M	81.2M	93.7M	98.4M
Property Plant And Equipment Gross	17.7M	9.0M	31.1M	30.9M	63.7M	66.9M
Total Current Assets	187.7M	375.7M	243.1M	248.6M	285.6M	148.7M
Accumulated Other Comprehensive Income	(12.0M)	0.0	(15.1M)	(31.3M)	(24.0M)	(22.8M)
Common Stock	50K	58K	71K	72K	73K	42.9K
Property Plant Equipment	8.9M	9.0M	31.1M	30.9M	35.5M	37.3M
Short Long Term Debt Total	13.6M	12.3M	18.9M	14.7M	12.6M	16.3M
Net Tangible Assets	171.7M	358.6M	185.9M	379.3M	436.2M	458.0M
Long Term Debt	25.2M	23.9M	694K	810K	931.5K	884.9K
Retained Earnings Total Equity	(246.7M)	(281.6M)	(357.2M)	(393.7M)	(354.3M)	(372.1M)
Long Term Debt Total	25.2M	23.9M	694K	810K	931.5K	884.9K
Capital Surpluse	486.1M	702.8M	1.5B	1.5B	1.7B	1.8B
Deferred Long Term Liab	4.2M	3.9M	5.6M	4.5M	5.2M	4.3M
Intangible Assets	65.0M	59.9M	202.7M	174.9M	88.6M	66.2M
Short Term Debt	1.4M	1.6M	4.8M	4.1M	5.1M	6.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

IAUM	iShares Gold Trust
C	Citigroup
V	Visa Class A

When determining whether Veracyte is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Veracyte Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Veracyte Stock. Highlighted below are key reports to facilitate an investment decision about Veracyte Stock:

How To Invest In Veracyte

Details

Is Veracyte Stock a good investment?

Details

What is Veracyte's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veracyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.

You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Complementary Tools for Veracyte Stock analysis

When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.

	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	CEOs Directory Screen CEOs from public companies around the world
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules

Is Veracyte's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Veracyte. If investors know Veracyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Veracyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.93)

Revenue Per Share

5.123

Quarterly Revenue Growth

0.175

Return On Assets

(0.01)

Return On Equity

(0.06)

The market value of Veracyte is measured differently than its book value, which is the value of Veracyte that is recorded on the company's balance sheet. Investors also form their own opinion of Veracyte's value that differs from its market value or its book value, called intrinsic value, which is Veracyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Veracyte's market value can be influenced by many factors that don't directly affect Veracyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Veracyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Veracyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Veracyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Veracyte Common Stock vs Accounts Payable Analysis

Common Stock vs Accounts Payable

Common Stock vs Accounts Payable Correlation Analysis

Correlation Coefficient

Common Stock

Accounts Payable

Veracyte fundamental ratios Correlations

Veracyte Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Veracyte fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Veracyte Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab
Cash And Short Term Investments	+ 1.0	Cash
Other Stockholder Equity	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Other Current Liab
Non Current Assets Total	+ 0.99	Total Current Liabilities

Cash And Short Term Investments	- 0.97	Net Debt
Cash	- 0.97	Net Debt
Common Stock Total Equity	- 0.95	Retained Earnings
Other Stockholder Equity	- 0.94	Retained Earnings
Net Receivables	- 0.94	Retained Earnings
Total Current Assets	- 0.94	Net Debt